Olezarsen significantly remodels Lp(a) particles by reducing their TG and cholesterol content, without affecting Lp(a) concentration, according to results from a Phase 2 dose ranging study of the apoC3 inhibitor recently approved in the USA for use in adults with familial chylomicronaemia syndrome (FCS).
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
